US Capitol Capsule: Barriers to PCSK9s use: What to expect

While Sanofi and Regeneron Pharmaceuticals said the FDA granted what the companies perceived as a "pretty broad label" for Praluent (alirocumab) – the first proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor approved in the US to lower low density lipoprotein cholesterol (LDL-C) when statins are not enough – the firms said they anticipated some barriers to the drug's use in the US.